Association between the rs4784227-CASC16 polymorphism and the risk of breast cancer: A meta-analysis. Issue 34 (26th August 2022)

• Record Type: Journal Article
• Authors: Xu, Wenji; Zhong, Yao; Yang, Haihui; Gong, Yuhan; Dao, Jun; Bao, Liping
• Is Part Of: Medicine. Volume 101:Issue 34(2022)
• Page Start: e30218
• Publication Date: 2022-08-26
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000030218
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Objective: Although several studies have identified an association between the rs4784227-cancer susceptibility candidate gene 16 (CASC16) polymorphism and breast cancer, the results remain inconclusive. Therefore, we conducted a meta-analysis to assess the relationship between the rs4784227-CASC16 polymorphism and breast cancer risk. Methods: Studies were searched in the PubMed, Web of Science, Embase, Google Scholar, and Cochran Library databases until June 10, 2021, to identify all potential literature on rs4784227-CASC16 polymorphism and breast cancer risk association. Fixed-effect or random-effect models were used to calculate odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs). Subgroup analyses, publication bias, and sensitivity analyses were also conducted. Results: Seventeen eligible studies involving 34, 719 subjects (18, 445 cases and 16, 274 healthy controls) from 7 articles were included in the current meta-analysis. The pooled ORs regarding the association between the rs4784227-CASC16 polymorphism and breast cancer risk were statistically significant [T vs C: OR = 1.244, 95% CI = 1.202–1.287; TT vs CT + CC: OR = 1.407, 95% CI = 1.296–1.528; CC vs CT + TT: OR = 0.777, 95% CI = 0.745–0.811; TT vs CC: OR = 1.544, 95% CI = 1.419–1.681; CT vs CC: OR = 1.244, 95% CI = 1.189–1.301]. On subgroup analysis, the rs4784227-CASC16 T/C gene has a certain correlation with breast cancer susceptibility in Asian and North American populations, but no significant risk in the Australian population. Conclusion: Our pooled analysis showed a significant association between the rs4784227- (T) allele and breast cancer susceptibility in Asian and North American populations, and intervention with this mutation might be a new therapeutic strategy for breast cancer. However, large-scale and well-designed studies are needed in different populations to further evaluate the role of the rs4784227-CASC16 polymorphism in breast cancer.